US Edition
Tylenol-Maker Kenvue Fires CEO Thibaut Mongon, Hires Kirk Pery as Interim CEO
SUMMIT, NEW JERSEY, JUL 14 – Kenvue appointed Kirk Perry as interim CEO amid activist pressure to enhance profitability and is conducting a strategic review to optimize its brand portfolio and unlock shareholder value.
- On July 14, 2025, Kenvue fired Thibaut Mongon, named Kirk Perry as interim CEO and launched a strategic review.
- Barely 15 months post-spin-off, investors demanded change, prompting Monday’s leadership shake-up as shareholder pressure and declining sales fueled calls for a sale to unlock value.
- Kenvue formed a special board committee advised by Centerview Partners and McKinsey & Co. to explore portfolio simplification and potential divestitures, as Larry Merlo said “The Board's strategic review is underway.”
- Following the leadership transition, Kenvue shares barely budged, and Kirk Perry said “I am excited to leverage my decades of experience.”
- On Aug. 7, Kenvue will report full quarterly results and revise its full-year outlook, expects adjusted earnings per share of 28 to 29 cents and is working with Heidrick & Struggles on a CEO search.
26 Articles
26 Articles
Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors
Two years ago, when Johnson & Johnson announced it was spinning off its consumer brands including Tylenol, Band-Aid, Motrin, Sudafed, and Neutrogena into a new company called Kenvue, investor anticipation was high. The thinking was simple: The company was packed with household names that had room to grow, untethered from all the problems of the J&J mothership. Kenvue shares rose 22% in their trading debut in May 2023. But the honeymoon was short…
Coinbase Gains; Kenvue Leadership Change; Synopsis Early Move Up - Stock Movers
On this episode of Stock Movers: Coinbase (COIN) share are gaining after Argus Research Corp initiated coverage of the stock with a recommendation of buy and a $400 price target. The stock has 20 analyst buy, 16 hold and four sell ratings with an average price target of $315, according to data compiled by Bloomberg; shares are up 56% year-to-date. Kenvue (KVUE) is moving after it said Chief Executive Officer Thibaut Mongon will leave the company…
Associated Press News
Kenvue CEO Mongon leaves the consumer health company as it continues its strategic review
Kenvue says that CEO Thibaut Mongon is departing as the maker of Listerine and Band-Aid brands continues with a strategic review of the company.
Coverage Details
Bias Distribution
- 73% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
